|
SYNARC to Attend the CTAD, ACR, AHA, and RSNANewark, CA – October 24, 2011 - SYNARC, the world's leading provider of medical imaging services for the pharmaceutical, biotechnology, and medical device industries, would like to announce that we will be attending the following upcoming conferences: The 4th annual Clinical Trials on Alzheimer's Disease (CTAD) conference brings together the current leaders involved in AD clinical trials to discuss the next generation of AD treatments and to harmonize the various neuroimaging techniques and their analyses. Dr. Jerome Barakos will give a presentation on the use of MRI for safety reads, titled MRI Features of ARIA-E Identified at Baseline in AD Study Cohorts, on Friday, November 4th from 9:45 to 10:00AM. The American College of Rheumatology (ACR) annual conference is a must-attend event for anyone involved in rheumatology research and clinical trials. Members of SYNARC's Science Team and Business Development Team will be in attendance. The American Heart Association (AHA) conference will focus on identifying cutting-edge research and technology in heart failure, atherosclerosis, stroke, cardiovascular genetics, molecular biology, and arrhythmias. Members of SYNARC's Science Team and Business Development Team will be in attendance. The 97th Radiological Society of North America (RSNA), one of the largest medical conventions in the world, will focus on the specialty's hottest topics from research to the clinic, radiology informatics, and learning opportunities in a range of disciplines and sub-specialties. Attendees come from more than 100 countries to participate in hands-on workshops, discussion groups, professional panels, and a technical exhibition featuring nearly 700 companies with the latest medical imaging equipment. Members of SYNARC's Science Team and Business Development Team will be in attendance. About SYNARC SYNARC has extensive expertise in cardiovascular imaging services including angiography, echocardiography, cardiac MRI, carotid intima media thickness (CIMT), intravascular ultrasound (IVUS) and other modalities to support cardiovascular clinical programs, as well as cardiac safety assessments in other therapeutic areas such as oncology and metabolic diseases. SYNARC continues to build its cardiovascular franchise and in particular, to broaden the range of imaging modalities it offers its clients for use in clinical trials. # # #
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| © Copyright 2012 SYNARC Inc. Legal Statement |